research Bitemporal Scalp Hair Loss: Differential Diagnosis of Nonscarring and Scarring Conditions
Understanding the cause of bitemporal hair loss is key to deciding the right treatment.
Search
forLearn
0 / 0 results — no results
Research
5 / 552 results research Supplementary Images & Discussion - Tolerated, Effective, Successful: Low Dose Oral Minoxidil for Treating Alopecia, A 3-Year North American Retrospective Case Series
Low-dose oral minoxidil effectively treats hair loss with good tolerance.
research Bitemporal Alopecia: A Unique Pattern Variant of Alopecia
The document concludes that "hot comb alopecia" is now called "central cicatricial centrifugal alopecia" and its causes are complex.
research Chest Hair Used as Donor Material in Hair Restoration Surgery
Chest hair can be used for scalp hair transplants when there's not enough scalp hair.
research Cancer-Related Alopecia Risk And Treatment
Scalp cooling helps prevent hair loss during chemotherapy, and minoxidil aids regrowth.
Community Join
3 / 3 results
community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
community Kintor stealing pictures from a hair transplant clinic to promote their failed product (KX826, Pyrilutamide)
Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.